Dr Pablo Corral

Pharmacology & Research Department, School of Medicine, FASTA University, Mar del Plata, Argentina

Dr. Pablo Corral is an Internal Medicine and Lipid Specialist, serving as Coordinator of the Lipids and Atherosclerosis Department at the ICM Institute in Mar del Plata, Argentina. He is also a Full Professor of Pharmacology at FASTA University, School of Medicine, in Mar del Plata. Additionally, he is the Past President of the Argentine Lipid Society (2022–2024) and has received numerous accolades, including the Arturo Allió Award for Best Research (2022).

Dr. Corral's primary research focus includes Lipids, Atherosclerosis, and Cardiovascular Disease prevention, with a particular emphasis on Familial Hypercholesterolemia, Residual Risk, and genetic dyslipidemias. He has led and participated in numerous clinical trials as Principal Investigator related to Atherosclerosis and Lipids, including the COLCOVID Trial (published in JAMA, 2022), PREPARE-IT I & II, and the Lp(a)HORIZON Study. He is also the National Lead Investigator for the CORAL-REEF Trial (MK-0616) and the EAS FH Studies Collaboration (FHSC) in Argentina.

Dr. Corral has published over 50 manuscripts in lipidology and atherosclerosis, with contributions to key guidelines such as the Argentine National Lipid Guidelines (2019), PCSK9 Inhibitor Guidelines (2018), and Familial Hypercholesterolemia Textbooks for the IberoAmerican FH Network. He has also co-authored several expert consensus documents on cardiovascular prevention.

He is an active member of leading scientific societies, including the European Atherosclerosis Society (EAS), International Atherosclerosis Society (IAS), FH Foundation, and the IberoAmerican FH Network. Dr. Corral frequently reviews for journals such as Atherosclerosis and the Journal of Clinical Lipidology, and serves as an editor for the Journal of Lipid and Atherosclerosis (JLA) and the Argentine Lipid Society Journal.

With over 250 lectures delivered at national and international conferences, Dr. Corral is a prominent voice in the field. He also chaired the 2024 European Atherosclerosis Society Congress.

Updated 17 January 2025